SCHEMBL5097334

SCHEMBL5097334

Fc1ccc(Sc2ncc3c(-c4ccccc4Cl)n[nH]c3n2)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 5/20 0.40
GSK3A P49840 4/20 0.40
DCUN1D1 Q96GG9 1/20 0.39
CNR1 P21554 2/20 0.38
CNR2 P34972 2/20 0.38
LMNA P02545 2/20 0.37
MEN1 O00255 3/20 0.34
KMT2A Q03164 3/20 0.34
ALDH1A1 P00352 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
RXFP1 Q9HBX9 1/20 0.33
HTR7 P34969 1/20 0.33
ALPL P05186 2/20 0.33
RAB9A P51151 2/20 0.33
NPC1 O15118 1/20 0.33
TP53 P04637 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2D6 P10635 1/20 0.33
CYP2C9 P11712 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5107013 0.91 DCUN1D1 (0.42) GSK3BGSK3ADCUN1D1CNR1KMT2A
SCHEMBL5093625 0.88 GSK3B (0.40) GSK3BGSK3ADCUN1D1CNR1CNR2
SCHEMBL4020901 0.85 GSK3A (0.39) GSK3BGSK3ADCUN1D1CNR1CNR2
SCHEMBL5100381 0.84 DCUN1D1 (0.39) GSK3BGSK3ADCUN1D1CNR1LMNA
SCHEMBL4011970 0.81 AURKA (0.47) GSK3BGSK3ADCUN1D1LMNAMEN1
SCHEMBL5106221 0.77 MAPK14 (0.40) GSK3BGSK3ACNR1CNR2MEN1
SCHEMBL5097291 0.73 MAPK14 (0.46) GSK3BGSK3AAURKAMAPK11MAPK14
SCHEMBL3252473 0.73 GSK3A (0.40) GSK3BGSK3AMAPTMAPK11MAPK14
SCHEMBL16447913 0.72 AURKA (0.43) GSK3BGSK3ADCUN1D1CNR1LMNA
SCHEMBL4014215 0.72 MAPK14 (0.58) GSK3BGSK3AMAPK11MAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7452880-B2 Substituted pyrazolo [3,4-d] pyrimidines and methods of using the same F. HOFFMANN-LA ROCHE AG (CH) 2008-11-18 US claimed
US-7452880-B2 Substituted pyrazolo [3,4-d] pyrimidines and methods of using the same F. HOFFMANN-LA ROCHE AG (CH) 2008-11-18 US disclosed
US-7452880-B2 Substituted pyrazolo [3,4-d] pyrimidines and methods of using the same F. HOFFMANN-LA ROCHE AG (CH) 2008-11-18 US disclosed
US-7452880-B2 Substituted pyrazolo [3,4-d] pyrimidines and methods of using the same F. HOFFMANN-LA ROCHE AG (CH) 2008-11-18 US disclosed
US-20050203091-A1 Heteroaryl-fused pyrazolo derivatives and methods for using the same ROCHE PALO ALTO LLC 2005-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050203091-A1 Heteroaryl-fused pyrazolo derivatives and methods for using the same MAP3K1, MAP3K21, MAP3K2 GSK3B 1767/4885GSK3A 2041/4885DCUN1D1 2414/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.